Wednesday, July 8, 2026

Patent intelligence · US

US 6399103

Method of producing a sustained-release preparation

expired A61KA61K38/27A61K9/143A61K9/146
Status expired
Linked drugs 3
Pipeline programs 6
Years to expiry 0
Applicant portfolio 1,436
Patent details — US 6399103
Jurisdiction
US
Status
expired
Grant date
Jun 4, 2002
Expiration
May 30, 2022
Claims
13
CPC classes
A61K, A61K38/27, A61K9/143, A61K9/146
View on Google Patents ↗

Quick answer

US 6399103 (Method of producing a sustained-release preparation) is held by Takeda Chemical Industries Ltd.. Status: expired. Granted Jun 4, 2002. Expires May 30, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
13
CPC classes
A61K, A61K38/27, A61K9/143, A61K9/146, A61K9/1611, A61K9/1647

More from Takeda Chemical Industries Ltd.

Related pharmaceutical patents in our USPTO index.

  1. US 12428403

    N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists

    Takeda Pharmaceutical Company Limited · Expires Sep 25, 2045

    granted
  2. US 12421188

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  3. US 12419890

    Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Sep 18, 2045

    granted
  4. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  5. US 12415782

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Expires Sep 11, 2045

    granted
  6. US 12409210

    CNS delivery of therapeutic agents

    Takeda Pharmaceutical Company Limited · Expires Sep 4, 2045

    granted
  7. US 12404237

    Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted
  8. US 12403154

    Administration of sting agonist and checkpoint inhibitors

    Takeda Pharmaceutical Company Limited · Expires Aug 28, 2045

    granted

Frequently asked questions

What is US patent 6399103?

US 6399103 (Method of producing a sustained-release preparation) is held by Takeda Chemical Industries Ltd.. Status: expired. Granted Jun 4, 2002. Expires May 30, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6399103?

Takeda Chemical Industries Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.

When does US 6399103 expire?

Our index shows an expiration date of May 30, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.